Alex Pasteur, Ph.D.


+44 (0)20 7074 5631


Alex Pasteur is a Partner with F-Prime Capital. He is based in London and leads the firm’s biomedical investment efforts in Europe. He has worked in healthcare investing since 2001. Alex focuses on investments in therapeutics and healthcare IT, a portfolio that includes Orchard Therapeutics (NASDAQ: ORTX) where he was also a company founder, Adaptimmune Therapeutics (NASDAQ: ADAP), Acacia Pharma (BRU: ACPH), Arvelle Therapeutics (acquired by Angelini Pharma), Genomics PLC, Oviva AG, Owkin, Pulmocide Ltd and Nodthera Ltd.

Prior to joining F-Prime in 2012, Alex worked at MVM Life Science Partners LLP in the USA and Europe and was responsible for investments in Cara Therapeutics Inc. (NASDAQ: CARA), Vantia Ltd and Xention Pharma Ltd.

Alex earned a M.A. in Natural Sciences from Cambridge University and a Ph.D. in Chemistry from Cambridge University.

  • Acacia Pharma (EURONEXT:ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Learn more at

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, United Kingdom

    • Year Invested


    • Team

  • Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Learn more at

  • Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market.  Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.

  • Genomics plc’s vision is to use genomic insights to transform the drug discovery industry by getting better drugs developed more quickly and targeted at the right group of patients. Learn more at

  • NodThera is a biotech engaged in innate immune/inflammasome research. Our leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. Learn more at

  • Orchard Therapeutics (NASDAQ:ORTX) Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Learn more at

  • Oviva is a new type of healthcare provider using technology to scale the dietitian workforce to help meet the growing number of patients with diet-related health conditions. Learn more at

  • Owkin combines life-science and machine learning expertise to make drug development and clinical trial design more targeted and more cost effective. Owkin’s machine learning algorithms create models that predict disease evolution and treatment outcomes. These predictive models are implemented in clinical trials for enhanced analysis, surrogate endpoints, patient stratification, patient selection, and high-value subgroup identification. The impact of this research is faster discovery of better treatments at a lower cost. Learn more at

  • Pulmocide is a biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Learn more at